Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003010752 | SCV003709087 | uncertain significance | Inborn genetic diseases | 2022-04-13 | criteria provided, single submitter | clinical testing | The c.1699A>G (p.I567V) alteration is located in exon 10 (coding exon 10) of the CFHR5 gene. This alteration results from a A to G substitution at nucleotide position 1699, causing the isoleucine (I) at amino acid position 567 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003143569 | SCV003831621 | uncertain significance | CFHR5 deficiency | 2022-01-17 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003143569 | SCV004177518 | uncertain significance | CFHR5 deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV004790455 | SCV005412747 | uncertain significance | not provided | 2024-02-20 | criteria provided, single submitter | clinical testing | BP4 |
Fulgent Genetics, |
RCV005011174 | SCV005634454 | uncertain significance | C3 glomerulonephritis | 2024-02-29 | criteria provided, single submitter | clinical testing |